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Thrombus lysis is the consequence of a restricted number of reactions localised on the surface 
of fibrin and cell membranes. A functional defect or an insufficient fibrinolytic response may 
lead to thrombosis with severe or fatal clinical consequences. Despite this clinical exigency 
and a real progress in the knowledge of the different components of this system (plasminogen 
activators, inhibitors and receptors) including structure-function relationship unveiled by the 
crystal structure of plasminogen, the functional evaluation of fibrinolysis still remains a 
challenge in haemostasis. The absolute requirement of a template for molecular assembly of 
plasminogen and its activators (tPA or uPA) restricts the formation of plasmin onto the 
surface of fibrin and cells. In contrast, during fibrinolysis plasmin and tPA released from the 
clot are immediately neutralised by their respective inhibitors, α2-antiplasmin and 
plasminogen activator inhibitor 1, PAI-1. It is therefore almost impossible to detect 
fibrinolytic activity in plasma with current methods or to measure the degree of fibrinolysis 
directly on clots unavailable in a clinical setting.  
Interestingly, it was recently discovered that circulating membrane microvesicles, which 
behave as messengers of cell activation, might be indicators of the fibrinolytic response to an 
inflammatory or prothrombotic process.1, 2 These fibrinolytic microvesicles transport at their 
membrane the plasminogen activators expressed by the cell of origin: tPA from endothelial 
cells and uPA from leukocytes.3 These microvesicles generate plasmin in situ upon binding of 
plasminogen to carboxy-terminal lysine residues of membrane receptors. Thus, co-assembly 
of plasminogen and its activator onto the same surface is required to trigger the fibrinolytic or 
proteolytic process classically described on cell membranes and fibrin. 
We recently discovered that moving surfaces such as microvesicles might also participate in a 
new mechanism of plasmin formation requiring a cross-talk between two different surfaces.2 
In this fibrinolytic cross-talk, one of the surfaces bearing uPA/uPAR (leukocyte or its 
microvesicles) can recognize and activate plasminogen carried by the other surface (platelets, 
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fibrin or extracellular matrix). Plasminogen thus bound adopts an open conformation that is 
readily transformed into plasmin. Recently published studies4-6 are in agreement with these 
hitherto unknown fibrinolytic pathway and potentially novel biomarkers in clinical practice.  
 
Relevance of the fibrinolytic cross-talk mechanism 
This novel mechanism of plasmin formation at the surface of platelets, extracellular matrix or 
fibrin by microvesicles bearing uPA raises the question of its involvement in different 
pathophysiological situations:  
 
Fibrinolysis: recanalisation of occluded vessels 
Platelets and derived microvesicles do not bear plasminogen activators. However, they 
can immobilise plasminogen on their surface via carboxy-terminal lysine residues-
dependent interactions.7 Platelets may thus contribute to increase the concentration of 
plasminogen within the clot. Microvesicles bearing uPA could then cross-talk with 
platelet-bound plasminogen thus allowing in situ plasmin formation and re-
canalisation of an occluded vessel. Similarly, activation of plasminogen bound to 
fibrin by leukocytes bearing uPA plays a role in endogenous fibrinolysis.6 
 
Cell migration and angiogenesis 
Aside from its fibrinolytic function, plasmin formation by the uPA/uPAR system is 
involved in tissue remodelling and plays a critical role in cell migration and 
angiogenesis. The ability of microvesicles to generate plasmin influences and 
modulates the repair process of endothelial progenitor cells. Small amounts of 
microvesicles bearing the uPA/uPAR system promote cell migration and angiogenesis 
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whereas at high concentrations excess plasmin leads to matrix degradation, decreased 
cell adhesiveness and finally apoptosis.1 
 
Dissemination of cancer cells  
Platelet microvesicles may promote metastasis and angiogenesis, 8 and high amounts 
of uPA/uPAR were associated with matrix degradation and loss of cell adhesion in 
advanced metastatic cancers.9 It is interesting to note that the described 
fibrinolytic/proteolytic cross-talk mechanism is only possible in the presence of uPA, 
which has been found on microvesicles emitted by cancer cells.  
 
Conclusion and potential applications 
The structure and function of the plasminogen activation system and its role in the 
maintenance of haemostasis and thrombosis prevention is now well established. However, 
detection of a dysfunction of this system remains a major challenge in clinical practice. 
Actually, plasminogen activators circulate at extremely low concentrations as inactive 
complexes with PAI-1 whereas active plasminogen activators are exclusively located on the 
cell membrane or fibrin. Since most measurements performed in plasma or its euglobulin 
fraction do not take into account the contribution of surface-bound plasminogen activators, it 
is impossible to quantify a lack of tPA or uPA activity that may be the cause of a fibrinolytic 
insufficiency. The recent discovery of fibrinolytic microvesicles and their role in fibrinolytic 
cross-talk, opened up new perspectives. We propose that the fibrinolytic activity conveyed by 
microvesicles could be the real source of fibrinolysis in circulating blood. These 
microvesicles would act on and within the clot, thus explaining the lack of systemic 
fibrinolysis. We suggest that the fibrinolytic activity of endothelial and leukocyte 
microvesicles compensates locally the activity of procoagulant microvesicles. Spontaneous 
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re-canalization in 15-20% ST-segment elevation myocardial infarction,10 could be thus 
explained by fibrinolytic microvesicles counterbalancing procoagulant microvesicles. At the 
opposite, a failure of timely fibrinolytic response by microvesicles would result in persistence 
of occluding thrombi. Accordingly, the functional balance between these two types of 
microvesicles would result in a physiological haemostatic response, while the lack of 
fibrinolytic microvesicles may allow thrombus formation. Within this context, it will be 
possible to use microvesicles as vectors of fibrinolysis and pericellular proteolysis. The 
existence of a hemorrhagic syndrome (Quebec platelet disorder) caused by profibrinolytic 
platelets having an abnormal expression of uPA is consistent with this hypothesis.11 
Transgenic mice that express uPA in their platelets are resistant to arterial thrombosis and 
transfusion of these platelets to control mice prevents occlusive arterial thrombi formation.12 
Similarly, addition of fibrinolytic microvesicles to plasma or euglobulins decreases the 
microplate clot lysis time in a concentration-dependent manner (unpublished results). 
Although the venous occlusion test induces the release of fibrinolytic microvesicles, the 
majority of fibrinolytic assays including the euglobulin clot lysis time, exclude microvesicle-
bound plasminogen activators (unpublished results). Thus, development of a new test for the 
detection of fibrinolytic microvesicles directly in plasma is promising as it will bring a new 
light to both the pathophysiology of fibrinolysis and the management of thrombosis in clinical 
practice.13 
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